Shire has agreed to buy US partner New River Pharmaceuticals for $2.6bn (£1.33bn) in a deal that gives it a replacement for its top selling drug which goes off patent in two years.

But the deal also means the UK speciality pharmaceuticals company is set to become an increasingly attractive takeover target, according to analysts.